Single-cell Sequencing 101: DNA & Multi-omics for Precision Medicine

Cancer is a complex disease that continuously evolves in response to environmental pressures. The dynamism and heterogeneity of tumours have significant clinical implications. In this eBook, we review how single-cell DNA sequencing and multi-omics are used to dissect clonal architecture, providing valuable insights for clinical strategies, disease modelling, and the development of cell and gene […]

Download the e-Book

Batch-to-batch consistency: premium grade bioactive proteins

From basic to translational research and clinical applications, cell culture is an essential technique that underpins the generation of promising cell and gene therapies. Since the quality of cytokines and growth factors can significantly influence the properties and function of cultured cells, these bioactive proteins must be produced to the highest standards to ensure the same reproducible […]

Download the Whitepaper

Weighing in Compliance with European Pharmacopoeia Chapter 2.1.7

European Pharmacopoeia (Ph. Eur.) General Chapter 2.1.7 Balances for Analytical Purposes was published in July 2021. Compliance with this chapter by January 1, 2022 is mandatory for any pharmaceutical company who manufactures in, or exports into, the European market.   Balances for Analytical Purposes aims to ensure quality control of medicines in European member states. The requirements of Ph. Eur. are similar […]

Download the Whitepaper

Cubis Laboratory Balances in Vaccine Research and Development

Vaccination is the most effective method of preventing infectious diseases, and is considered one of the greatest achievements in medicine. Until today, various vaccines against several crucial diseases (including influenza, chicken pox, or HPV) have been developed that save millions of lives. Along the continuous emergence of new diseases and concerns regarding safety, vaccine research […]

Download the Brochure

Antibody Discovery: From Target to Molecule

You’re about to embark on a journey of discovery. And like all journeys that are worthwhile, it’s far from linear. The process of antibody discovery and development into a clinical candidate is one full of twists, turns, roundabouts, and offshoots, yet one that an increasing number of researchers and companies, both small and large, have […]

Download the eBook

An industry perspective by 20/15 Visioneers, a leading science and technology consulting firm

John Conway of 20/15 Visioneers tackles defining “What Makes a Great BioELN” in this thoughtful and informative industry perspective. Learn: The six high-level workflows a great BioELN must include What are the team personas who must get utility from a new BioELN The 3 key qualities necessary to have in place before seeking a BioELN […]

Download the Whitepaper

Leaving the Wild West Era of Lipidomics

Leading research from European Journal of Lipid Science and Technology How many different types of diseases are there in the world? How will we ever be able to find cures for them? We might not be able to do so for all of them, but we may be able to develop better treatments. Scientific and […]

Download the Whitepaper

Disrupting Drug Discovery From Assay Development to Lead Compound

High-throughput screening remains one of the most powerful, unbiased approaches for small molecule drug discovery. In this white paper, SAMDI Tech CSO, Zack Gurard-Levin, discusses the important aspects to consider when choosing the right methodology for drug discovery. Learn: Traditional label-dependent approaches vs. novel label-free technologies How researchers determine which methodology offers the most promising […]

Download the Whitepaper

Do you need a custom monoclonal antibody for your next project?

Selecting the right custom antibody provider is an important decision. It can mean the difference between a breakthrough or failure. That’s why it matters in how and where your antibodies are made. Learn what sets Bethyl custom monoclonal antibodies quality and service apart. Discover the top reasons why you should choose Fortis Life Science for […]

Download the Infographic

Advancing quantitative analysis of targeted protein degrader compounds

Small molecule drug discovery is expanding beyond traditional strategies focused on identifying compounds that inhibit or block the activity of proteins that cause disease. A newer approach is to selectively target proteins for removal from the cell using degrader compounds. Proteolysis Targeting Chimeras (PROTACs) and immunomodulatory (IMiD) molecular glues are examples of small molecule degraders […]

Download the Whitepaper